Los Angeles Capital Management
ACRS icon

Los Angeles Capital Management’s Aclaris Therapeutics ACRS Stock Holding History

Los Angeles Capital Management’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-75,006
Closed -$778K – 1105
2023
Q2 		$778K Buy
+75,006
New +$679K ﹤0.01% 716
2019
Q1 		– Sell
-11,215
Closed -$83K – 1351
2018
Q4 		$83K Sell
11,215
-125
-1% -$1.29K ﹤0.01% 1243
2018
Q3 		$165K Hold
11,340
– – ﹤0.01% 1350
2018
Q2 		$226K Buy
+11,340
New +$210K ﹤0.01% 1353

Other funds holding ACRS

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Los Angeles Capital Management's ACRS Position: Q3 2023 in Review

Los Angeles Capital Management sold out of Aclaris Therapeutics (ACRS) in Q3 2023, closing a stake of 75,006 shares — an estimated $778K sold.

Los Angeles Capital Management first reported a position in ACRS in Q2 2018 and held it in 4 quarters. The position peaked at $778K in Q2 2023. 137 funds tracked by Wall St. Rank hold ACRS as of Q3 2023.

  • Los Angeles Capital Management reported no remaining Aclaris Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Los Angeles Capital Management sold 75,006 Aclaris Therapeutics shares in Q3 2023, an estimated $778K.
  • Los Angeles Capital Management first reported a position in Aclaris Therapeutics in Q2 2018 and held it in 4 quarters.
  • Los Angeles Capital Management's Aclaris Therapeutics position peaked at $778K in Q2 2023.
  • 137 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q3 2023.

Based on Los Angeles Capital Management's 13F filing for Q3 2023, filed 6 Nov 2023.